EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Stock Price & Overview

TSX:EPRX • CA29842P1053

11.04 CAD
-0.33 (-2.9%)
Last: Mar 3, 2026, 07:00 PM

The current stock price of EPRX.CA is 11.04 CAD. Today EPRX.CA is down by -2.9%. In the past month the price increased by 0.64%. In the past year, price increased by 83.69%.

EPRX.CA Key Statistics

52-Week Range3.96 - 12.86
Current EPRX.CA stock price positioned within its 52-week range.
1-Month Range10.09 - 12.41
Current EPRX.CA stock price positioned within its 1-month range.
Market Cap
573.418M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.65
Dividend Yield
N/A

EPRX.CA Stock Performance

Today
-2.9%
1 Week
-0.90%
1 Month
+0.64%
3 Months
+29.27%
Longer-term
6 Months +49.80%
1 Year +83.69%
2 Years +159.77%
3 Years +160.99%
5 Years +110.69%
10 Years N/A

EPRX.CA Stock Chart

EUPRAXIA PHARMACEUTICALS INC / EPRX Daily stock chart

EPRX.CA Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to EPRX.CA. When comparing the yearly performance of all stocks, EPRX.CA is one of the better performing stocks in the market, outperforming 78.55% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
EPRX.CA Full Technical Analysis Report

EPRX.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to EPRX.CA. EPRX.CA has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
EPRX.CA Full Fundamental Analysis Report

EPRX.CA Earnings

Next Earnings DateN/A
Last Earnings DateNov 4, 2025
PeriodQ3 / 2025
EPS Reported-$0.26
Revenue Reported
EPS Surprise -18.58%
Revenue Surprise %
EPRX.CA Earnings History

EPRX.CA Forecast & Estimates

8 analysts have analysed EPRX.CA and the average price target is 14.96 CAD. This implies a price increase of 35.54% is expected in the next year compared to the current price of 11.04.


Analysts
Analysts82.5
Price Target14.96 (35.51%)
EPS Next Y47.42%
Revenue Next YearN/A
EPRX.CA Forecast & Estimates

EPRX.CA Groups

Sector & Classification

EPRX.CA Financial Highlights

Over the last trailing twelve months EPRX.CA reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS decreased by -6.65% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-29.37M
Industry RankSector Rank
PM (TTM) N/A
ROA -31.81%
ROE -32.63%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-12.93%
Sales Q2Q%N/A
EPS 1Y (TTM)-6.65%
Revenue 1Y (TTM)N/A
EPRX.CA financials

EPRX.CA Ownership

Ownership
Inst Owners37.6%
Shares51.94M
Float42.73M
Ins Owners17.49%
Short Float %N/A
Short RatioN/A
EPRX.CA Ownership

EPRX.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
EDT SPECTRAL MEDICAL INC N/A386.179M
HBP HELIX BIOPHARMA CORP N/A160.398M
MDNA MEDICENNA THERAPEUTICS CORP N/A72.567M
COV COVALON TECHNOLOGIES LTD13.0451.926M
BCT BRIACELL THERAPEUTICS CORP N/A39.875M
RVX RESVERLOGIX CORP N/A34.507M
MBX MICROBIX BIOSYSTEMS INC5.9433.252M
HEM HEMOSTEMIX INC N/A15.62M
MPH MEDICURE INC N/A11.693M
CSCI COSCIENS BIOPHARMA INC N/A6.996M
KNE KANE BIOTECH INC N/A6.356M
QPT QUEST PHARMATECH INC N/A5.074M

About EPRX.CA

Company Profile

EPRX logo image Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.

Company Info

EUPRAXIA PHARMACEUTICALS INC

201-2067 Cadboro Bay Rd.

Victoria BRITISH COLUMBIA CA

CEO: James A. Helliwell

Employees: 33

EPRX Company Website

EPRX Investor Relations

Phone: 12505903968

EUPRAXIA PHARMACEUTICALS INC / EPRX.CA FAQ

Can you describe the business of EUPRAXIA PHARMACEUTICALS INC?

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.


What is the current price of EPRX stock?

The current stock price of EPRX.CA is 11.04 CAD. The price decreased by -2.9% in the last trading session.


What is the dividend status of EUPRAXIA PHARMACEUTICALS INC?

EPRX.CA does not pay a dividend.


What is the ChartMill rating of EUPRAXIA PHARMACEUTICALS INC stock?

EPRX.CA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What sector and industry does EUPRAXIA PHARMACEUTICALS INC belong to?

EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) operates in the Health Care sector and the Biotechnology industry.


Would investing in EUPRAXIA PHARMACEUTICALS INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EPRX.CA.